MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Spanning nine influenza seasons, these studies enrolled 1862 patients, of whom 954 received the high-dose vaccine and 908 the standard-dose vaccine. Primary outcomes were immunogenicity (measured ...

The Subject Expert Committee (SEC) under the COVID-19 division of the Central Drugs Standard Control Organization (CDSCO) has ...

"An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic ... pivotal efficacy, immunogenicity and ...

Immunogenicity of Trivalent Influenza Vaccine in Extremely Low-birth-weight, Premature versus Term Infants. ... (HA) units in 0.025 mL of the virus suspension. H1, H3, B/Victoria, ...

Novavax's stand-alone trivalent flu and dual Covid-19-influenza vaccines had similar immune responses to those seen in other licensed brands, according to phase 3 trial data. The Gaithersburg, Md ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

In opening Wednesday’s meeting, newly appointed ACIP chair Martin Kulldorff, Ph.D., leaned into the controversy surrounding U ...

The added scrutiny of the MMRV vaccine on the ACIP agenda comes against the backdrop of brisk measles activity, fueled by ...